Table 1 Available data on surrogate endpoints in mature B-cell neoplasms.
From: Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading?
Authors/Study | Lymphoma Subtype | Numbers of patients/trials | IPD | Surrogate Endpoint/True Endpoint | Individual /patient- level surrogacy | Trial-level surrogacy |
|---|---|---|---|---|---|---|
Beauchemin et al. [21] | CLL | 23 trials | No | PFS/OS | Rho: 0.813 | NA |
Shi et al. [23] | FL | 13 trials, 3837 patients | Yes | OR CR30/HR PFS | OR CR30/PFS 11.8 | R2WLS: 0.88 R2Copula:0.86 |
Zhu et al. [33] | FL MCL | 52 trials, 5542 patients 32 trials, 1425 patients | No | 6MoPFS/3year PFS 6MoPFS/Median PFS 6MoPFS/2year OS 6MoPFS/Median OS | R2: 0.89 R2: 0.66 R2: 0.69 R2: 0.71 | NA |
Simon et al. [22] | CLL | 12 trials, 4237 patients + external dataset 9 trials with 3993 patients | Yes + No for external dataset | PFS/OS MRD/PFS MRD/OS | 24MoPFS/60Mo OS: Rho 0.97 HR PFS uMRD vs. MRD: 4.74 HR OS uMRD vs. MRD: 3.02 | HR PFS/OS R: 0.75 R2: 0.56 OR MRD/HR PFS R: 0.88 R2: 0.78 OR MRD/HR OS R: 0.71 R2: 0.5 |
Bahar et al. [29] | CLL | 29 trials | No | ORR/PFS PFS/OS | Rho = 0.58 | Rho = 0.58 |
Milrod et al. [34] | FL | 22 trials, 10,729 patients | No | HR PFS/OS | NA | LWR: 0.383 R2: 0.15 |
